Antibody News and Research RSS Feed - Antibody News and Research

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.
Breakthrough antibody therapy shows significant promise against drug-resistant multiple myeloma

Breakthrough antibody therapy shows significant promise against drug-resistant multiple myeloma

In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana-Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine. [More]
iCo Therapeutics incurs total comprehensive loss of $738,607 for second quarter 2015

iCo Therapeutics incurs total comprehensive loss of $738,607 for second quarter 2015

iCo Therapeutics, today reported financial results for the quarter ended June 30, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). [More]
Long lasting flu vaccine using antibodies advance from TSRI and Janssen

Long lasting flu vaccine using antibodies advance from TSRI and Janssen

Scientists from The Scripps Research Institute (TSRI) and the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) have found a way to induce antibodies to fight a wide range of influenza subtypes—work that could one day eliminate the need for repeated seasonal flu shots. [More]
MorphoSys, Immatics partner to develop novel antibody-based therapies against multiple proprietary cancer antigens

MorphoSys, Immatics partner to develop novel antibody-based therapies against multiple proprietary cancer antigens

MorphoSys AG and Immatics Biotechnologies GmbH announced today a strategic alliance to generate novel antibody-based therapeutics against multiple proprietary cancer antigens recognized by T cells. [More]
Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Amgen today announced that it will present six abstracts at the upcoming ESC Congress 2015, organized by the European Society of Cardiology, being held Aug. 29 – Sept. 2 in London. [More]
Study: Influenza vaccines offer sustained protection up to 6 months during flu season

Study: Influenza vaccines offer sustained protection up to 6 months during flu season

Individuals who received the flu vaccine were protected for up to 6 months post-vaccination, the duration of most flu seasons, according to a study presented at the 2015 International Conference on Emerging Infectious Diseases. [More]
TSRI, Janssen collaborate to find universal flu vaccine

TSRI, Janssen collaborate to find universal flu vaccine

Scientists from The Scripps Research Institute and the Janssen Pharmaceutical Companies of Johnson & Johnson have found a way to induce antibodies to fight a wide range of influenza subtypes—work that could one day eliminate the need for repeated seasonal flu shots. [More]
Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

Esperance Pharmaceuticals Inc. today announced that it has entered into a strategic alliance agreement with MD Anderson Cancer Center to accelerate the clinical development of its lead anti-cancer candidate EP-100 for the treatment of ovarian cancer and to collaborate on preclinical studies of EP-100 as a treatment for breast cancer. [More]
Three projects that focus on improving global health win DEBUT Challenge

Three projects that focus on improving global health win DEBUT Challenge

Three unique projects focused on improving global health won the National Institutes of Health's Design by Biomedical Undergraduate Teams (DEBUT) Challenge. The winners showed exemplary initiative in designing tools for a less expensive, portable device to monitor HIV treatment, a new surgical clamp to treat drooping eyelids, and a low-cost patient monitor. [More]
AbVitro launches PairMe Grant Challenge to provide access to AbPair technology

AbVitro launches PairMe Grant Challenge to provide access to AbPair technology

AbVitro Inc., an immuno-oncology discovery company, today announced access to its AbPairTM technology by launching the "PairMe Grant Challenge." [More]
STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN (plitidepsin) in Australia and New Zealand. [More]
Experimental MERS-CoV vaccine shows promise in monkeys and camels

Experimental MERS-CoV vaccine shows promise in monkeys and camels

National Institutes of Health scientists and colleagues report that an experimental vaccine given six weeks before exposure to Middle East respiratory syndrome coronavirus (MERS-CoV) fully protects rhesus macaques from disease. The vaccine also generated potentially protective MERS-CoV antibodies in blood drawn from vaccinated camels. [More]
Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira today announced that Inflectra (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS). [More]
NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance the development of Soligenix's heat stabilized ricin toxin vaccine, RiVax. [More]
EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

EnGeneIC Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, today announced that the first patient has been dosed in its Phase 1 Tailored-EDV trial. The trial is being conducted at the Northern Cancer Institute in Sydney, Australia. [More]
Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros Corporation today announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) – aggregations of platelets – in the microcirculation of the body's organs, most commonly the kidney and brain. [More]
Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

United Therapeutics Corporation announced today that the European Commission (EC) has granted Marketing Authorisation for Unituxin (dinutuximab) for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT). [More]
Risk for endophthalmitis no higher with Avastin, finds study

Risk for endophthalmitis no higher with Avastin, finds study

Eye injections of the drug Avastin, used to treat retinal diseases, bring no greater risk of endophthalmitis, a potentially blinding eye infection, than injections with the much more expensive drug Lucentis made by the same company, according to new research from the Perelman School of Medicine at the University of Pennsylvania. Their findings are published today in JAMA Ophthalmology. [More]
Improved method for building proteins into antibodies

Improved method for building proteins into antibodies

Some proteins exist so fleetingly in the bloodstream that they can't be given effectively as therapies. However, building them into larger proteins, such as antibodies, can make them persist long enough to be useful. Now a team led by scientists at The Scripps Research Institute (TSRI) has devised an improved method for accomplishing this protein-engineering feat. [More]
TSRI-led team devises selection-based, protein-engineering method to work on obesity therapy

TSRI-led team devises selection-based, protein-engineering method to work on obesity therapy

Some proteins exist so fleetingly in the bloodstream that they can’t be given effectively as therapies. However, building them into larger proteins, such as antibodies, can make them persist long enough to be useful. Now a team led by scientists at The Scripps Research Institute has devised an improved method for accomplishing this protein-engineering feat. [More]
Advertisement
Advertisement